# US 2026/0097128 A1 · Detoxified Cholera Toxin as a Vaccine Adjuvant for Oral Vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097128 A1
- Document ID: US20260097128A1
- Status: Published application
- Kind: A1
- Application number: 19/352,224
- Filed: 2025-10-07
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Assignees: Inventprise, LLC
- Applicants: Inventprise, Inc.
- Inventors: Subhash V. Kapre
- Web page: https://patentgrep.com/patent/US20260097128A1

## CPC

- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 2039/55544: {Bacterial toxins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is directed to immunogenic compositions and vaccines, and methods for the manufacture and treatment and prevention of infections and, in particular, the preparation of immunogenic compositions and vaccines administered in conjunction with a detoxified cholera toxin as an adjuvant and a TLR agonist for oral administration, which may be encapsulated.

## Claims

### Claim 1

A complex comprising:
an immunological composition containing an immunologically active agent; and
a detoxified cholera toxin.

### Claim 2 (depends on 1)

The complex of claim 1, wherein the immunologically active agent is conjugated to the detoxified cholera toxin.

### Claim 3 (depends on 1)

The complex of claim 1, which is a tablet or capsule.

### Claim 4 (depends on 1)

The complex of claim 1, which is a paste or liquid.

### Claim 5 (depends on 1)

The complex of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1)

The complex of claim 1, further comprising a toll-like receptor agonist.

### Claim 7 (depends on 1)

The complex of claim 1, wherein the toll-like receptor agonist is conjugated to the immunologically active agent and/or the detoxified cholera toxin.

### Claim 8 (depends on 1)

The complex of claim 1, which is encapsulated.

### Claim 9 (depends on 1)

A method for the manufacture of the complex of claim 1 comprising;
obtaining the immunological composition containing the immunologically active agent;
detoxifying cholera toxin;
conjugating the agent to the detoxified cholera toxin forming the complex; and
isolated the complex.

### Claim 10 (depends on 9)

The method of claim 9, further comprising conjugating the complex with a toll-like receptor agonist.

### Claim 11 (depends on 9)

The method of claim 9, further comprising encapsulating the isolated complex.

### Claim 12 (depends on 9)

The method of claim 9, further comprising freeze drying the isolated complex.

### Claim 13 (depends on 9)

The method of claim 9, further comprising adding a pharmaceutically acceptable carrier to the isolated complex.

### Claim 14 (depends on 1)

A method for administering the complex of claim 1 to an individual comprising:
obtaining the complex;
administering the complex to an individual wherein administration is oral, intranasal or transdermal.

### Claim 15 (depends on 14)

The method of claim 14, wherein the complex is a tablet or capsule and administration is oral.

### Claim 16 (depends on 14)

The method of claim 14, wherein the complex is a paste, gel, or liquid and administration is transdermal via microneedles.
